Navigation Links
L’Oréal Fellowship winner seeks to improve blood cancer treatments
Date:8/21/2012

A desire to improve the survival of people with blood cancers and reduce the side-effects of their anti-cancer treatments has seen Walter and Eliza Hall Institute researcher Dr Kylie Mason today win one of three 2012 L'Oral Australia For Women in Science Fellowships.

The work of Dr Mason, a senior postdoctoral fellow in the institute's Cancer and Haematology division and a clinical haematologist at The Royal Melbourne Hospital, has set the benchmark for evaluating a new class of anti-cancer agents called BH3-mimetics.

In 2006 Dr Mason was part of the Walter and Eliza Hall Institute team which found that the BH3-mimetic ABT-737 ceased being effective in the presence of a protein called Mcl-1. "Mcl-1 is switched on in many tumours so this finding had significant repercussions for the development of BH3-mimetics, which hold promise for treating chemotherapy-resistant tumours," Dr Mason said.

Her subsequent studies showed that ABT-737 remained effective in killing chemotherapy-resistant tumours when combined with standard chemotherapy. They also revealed the first chapters of a much bigger story: that of platelets and their lifespan.

One of the side-effects of treatment with ABT-737 is acute thrombocytopenia (low platelet count). Dr Mason's studies have shown that while ABT-737 is directly toxic to circulating platelets, it does not affect their production in the bone marrow. "This finding provided the first indication that platelets could undergo programmed cell death," Dr Mason said.

In collaboration with Dr Ben Kile and others at the Walter and Eliza Hall Institute, Dr Mason showed that platelets the blood cells responsible for clotting are programmed to die, containing a molecular 'clock' that dictates their lifespan.

"This work has profound implications for the diagnosis and treatment of disorders that affect platelets," she said. "It also has critical implications for improved blood bank storage of platelets. The possibility of manipulating platelets to enhance their life span and increase storage life could revolutionise platelet transfusion therapy."

Dr Mason said she would use some of the $25,000 L'Oral Fellowship to attend the American Society of Hematology Annual Meeting where she will present data on the BH3-mimetic and platelet projects. "Receiving the fellowship is a great honour. As well as facilitating the professional interactions that will be available to me at the haematology meeting, the fellowship will allow me to employ a research assistant and continue the research program while I am fulfilling my clinical commitments."

Dr Mason is the fourth Walter and Eliza Hall Institute scientist to receive a L'Oral Australia For Women in Science Fellowship. Dr Marie-Liesse Asselin-Labat received the fellowship in 2010 for her breast cancer research, Marnie Blewitt (2009) for her research on epigenetics and Dr Erika Cretney (2008) for her studies of the immune system.


'/>"/>
Contact: Penny Fannin
fannin@wehi.edu.au
61-417-125-700
Walter and Eliza Hall Institute
Source:Eurekalert

Related medicine news :

1. Loyola Stritch, Niehoff students receive prestigious Schweitzer Fellowships
2. Fewer prostate cancer surgery complications found in teaching hospitals with fellowship programs
3. Damon Runyon Cancer Research Foundation grants fellowship awards to 21 top young scientists
4. MCG student receives national medical honor society research fellowship
5. Which ads are winners? Your brain knows better than you do
6. Nordic Walking a Winner for Heart Failure Patients, Study Says
7. USHEALTH Advisors L.L.C. Honored as Bronze Stevie® Award Winner in 2012 American Business Awards
8. Excellence Initiative winner TU München invests in the future: Young researchers
9. FDA Seeks to Limit Antibiotics in Animal Feed
10. Trial seeks to sniff out cancer
11. Electronic data methods research seeks to build a learning health care system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: